Darunavir: A Versatile Protease Inhibitor against Microbial Infections

Microbial infections continue to pose significant threats to global health, necessitating the development of innovative therapeutic strategies. One promising avenue is the use of protease inhibitors, with darunavir (DRV) emerging as a potent candidate in the field. Designed to combat resistance to standard HIV therapy, DRV is a second-generation protease inhibitor. Regarding microbial infections, this study sheds light on the internal processes behind the impact of DRV within cells. Novel protease inhibitor DRV targets essential proteolytic enzymes that are essential for microbial survival and growth in order to achieve its antimicrobial actions. By interfering with the proteolytic digestion of important microbial proteins, its inhibitory effect prevents infectious particles from being assembled and maturing. DRV is a viable treatment option for microbial infections as its selective suppression reduces the possibility of off-target consequences. DRV efficiently penetrates the intracellular milieu of host cells, where it prevents the proteolytic cleavage of vital viral and bacterial proteins, hence combating pathogenic infections. Microbial infections may be treated in a variety of ways using DRV as it disrupts the cycle of pathogen reproduction. The present review explores the molecular principles behind the effectiveness of DRV against microbial infections, emphasizing the drug's ability to fight a wide range of pathogens. The comprehension of the intracellular activity of DRV is promising for the creation of novel treatment approaches, providing encouragement in the continuous fight against microbial diseases.